Inhaled Allergen Challenge Methodology: Assessment of a Vibrating Mesh Nebulizer for Allergen Administration

Study Overview
=================
Brief Summary
-----------------
This study will assess the Aerogen Solo® (Solo®) vibrating mesh nebulizer as a potential new device for use in allergen challenge testing.

Detailed Description
-----------------
This will be a multi-center, randomized, cross-over study utilizing the expertise of three Canadian academic centers (University of Saskatchewan, McMaster University, Laval University) that have been performing allergen inhalation challenges and other bronchoprovocation studies for more than forty years. Each participant will be required to attend the research lab on five occasions (Visits 1-5). At Visit 1, study staff will provide an overview of the study purpose and procedure and answer any questions the participant may have. The individual will then provide consent if they wish to participate (i.e. sign the consent form). Skin prick testing to determine relevant allergen sensitivities and to determine which allergen extract will be used for the skin test endpoint (STE) and allergen inhalation challenge will then be performed. The participant will be randomized with respect to which nebulizer (Solo® or Wright) will be used first. The choice of nebulizer for the first participant will be via blinded draw. Subsequent nebulizer assignments will alternate. Participants will undergo the STE procedure and methacholine challenge testing (MCT) at visit 2; an allergen challenge will be done the next day at Visit 3 using the same nebulizer as was used for the MCT at Visit 2. Visits 4 and 5 will also be performed on consecutive days and will involve methacholine and allergen challenge testing, respectively, using the nebulizer that was not used at Visits 2 and 3. A minimum of two weeks must separate Visits 3 and 4.

Official Title
-----------------
Inhaled Allergen Challenge Methodology: Assessment of a Vibrating Mesh Nebulizer for Allergen Administration

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Device: Wright jet nebulizer
* Device: Aerogen Solo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: baseline FEV1 greater than or equal to 70% positive response to inhaled methacholine (i.e. PD20 less than 400mcg) evidence of atopy (i.e. positive skin prick test to an allergen that can be used for the inhalation challenge absence of respiratory infection for at least 4 weeks absence of allergen exposure (or other trigger of upper or lower respiratory symptoms) for at least 4 weeks current nonsmoker (ex-smoker allowed; case by case basis; investigator discretion) require only infrequent short-acting beta2 agonist (i.e. salbutamol or terbutaline) to treat/control asthma (i.e. no inhaled corticosteroid or combination therapies, no intranasal corticosteroid; anti-histamines etc.) general good health with no other medical condition, medication use or lifestyle activities that would influence the outcome of the allergen challenge Exclusion Criteria: pregnant or lactating

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Wright jet nebulizer<br>Will employ the Wright jet nebulizer for use in an allergen challenge triad | Device: Wright jet nebulizer<br>* Roxon Medi-Tech, Montreal, QC, Canada<br>|
| Experimental: Solo vibrating mesh nebulizer<br>Will employ the Aerogen Solo vibrating mesh device for use in an allergen challenge triad | Device: Aerogen Solo<br>* Aerogen Ltd., Galway, Ireland<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Allergen Solo EAR PD20 (provocative dose causing a 20% fall in forced expiratory volume, FEV1) | Record the dose of allergen required to induce a 20% fall in forced expiratory volume using the Solo device | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Predicted allergen Solo EAR PD20 | Will be predicted using the standard equation that employs the STE and MCT results | Baseline (based on baseline methacholine challenge and skin test endpoint results) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vibrating mesh nebulizer, allergen challenge